Development of tivantinib as treatment for hepatocellular carcinoma

Journal of Clinical and Translational Hepatology

Volumn 1, Issue 1, 2013, Pages 75-78

  Au, Jennifer ^a   Frenette, Catherine ^a  

^a SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

C Met; Hepatocellular carcinoma; Liver cancer; Tivantinib; Tyrosine kinase inhibitor

Indexed keywords

EID: 84937021106     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2013.00008     Document Type: Review

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: Where do we go now? Clin Cancer Res 2010;16:390–397.
3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Digest Liver Dis 2010;42 (Suppl 3):S206–S214.
4. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008;28:160–174.
5. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53–62.
6. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768–771.
7. Borowiak M, Garratt AN, Wustefelt T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004;101:10608–10613.
8. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic pro-gramme for cancer and stem cells. Nat Rev Cancer 2006;6:637–645.
9. Christensen JG, Burrows J, Salgia R. C-Met as a target for human cancer and characterization of the inhibitors for therapeutic intervention. Cancer Lett 2005;225:1–26.
10. Venepalli NK, Goff L. Targeting the HGF-cMET axis in hepatocellular carcinoma. Int J Hepatol 2013; 341636, Epub31 Mar 2013.
11. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001;411: 355–365.
12. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582–1595.
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
14. Munshi N, Jeay S, Li Y, Chen C, France DS, Ashwell MA, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544–1553.
15. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I trial of a selective c-Met inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271–1279.
16. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011;17:7754–7764.
17. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, et al. A Phase-1b study of Tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013;108:21–24.
18. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethern JL, et al. Tivantinib for second line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55–63.
19. www.clinicaltrials.gov, accessed June 2013.